Estrogen receptor α and β polymorphisms:: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy?
Estrogen receptor α and β polymorphisms:: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy?
复制标题
DOI：
10.1097/01.gme.0000182804.14385.a2
复制
发表时间：
2006-05-01
影响因子：
2.7
通讯作者：
Brandi, Maria Luisa
中科院分区：
文献类型：
--
作者：
Silvestri, Sandra;Thomsen, Anne Bloch;Brandi, Maria Luisa
目标和设计：对1098名绝经后妇女进行了雌激素受体（ER）基因多态性（ER α中的Pvull和Xbal，ER β中的Pvull和Xbal）与腰椎和前臂骨密度以及血脂谱的横断面分离分析。此外，在一个280名妇女的亚群，谁完成了1年的治疗与雌激素加rexestin，基因型之间的关联和治疗的反应，在血脂和骨进行了调查。在另一个未经治疗的443名妇女的亚群，基因型的影响，在平均随访期11年的椎骨骨折的患病率和骨丢失的年速率进行了estimated.Results：基线血脂，骨密度，骨丢失的年速率和脊柱骨折的患病率与ER α基因的多态性没有显着相关。ER β基因多态性与前臂远端骨丢失显著相关（P=0.04），但与脊柱骨丢失无关。激素治疗1年后，ER β多态性与总胆固醇的反应也有显著相关性。（P=0.02）;而ER α基因多态性并未显着影响对激素治疗的反应。结论：在大量绝经后妇女的白色人群中，ER α基因多态性与基线或激素治疗后的骨密度或血脂谱无关。相反，ER β基因型似乎与前臂骨丢失分离，并在激素治疗期间调节总胆固醇的降低。
Objective and design: A cross-sectional segregation analysis of polymorphisms in the estrogen receptor (ER) genes (Pvull and Xbal in ER alpha, and Alul in ER beta) with bone mineral density in the lumbar spine and forearm and with lipid profile was performed in 1098 postmenopausal women. Additionally, in a subpopulation of 280 women, who completed 1 year of treatment with estrogen plus progestin, the association between genotypes and the response to treatment in both plasma lipids and bone was investigated. In another untreated subpopulation of 443 women, genotype influence on the prevalence of vertebral fractures and on annual rate of bone loss during a mean follow-up period of 11 years was estimated.Results: Baseline plasma lipids, bone mineral density, annual rate of bone loss and prevalence of spinal fractures were not significantly associated with polymorphisms in the ER alpha gene. The ER beta polymorphism was significantly associated with bone loss from the distal forearm (P=0.04) but not with bone loss from the spine. After 1 year of treatment with hormone therapy there was also a significant association between the ER beta polymorphism and the response in total cholesterol (P=0.02); while the ER alpha gene polymorphisms did not significantly influence the response to hormone therapy.Conclusions: In a large white population of postmenopausal women, ER alpha gene polymorphisms were not associated with bone mineral density or lipid profile at baseline or after hormone therapy. Conversely, the ER beta genotype appeared to segregate with bone loss from the forearm and to modulate the decrease in total cholesterol during hormone therapy.